145 related articles for article (PubMed ID: 26676222)
21. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.
Kobayashi H; Fujishiro S; Terao T
Cancer Res; 1994 Dec; 54(24):6539-48. PubMed ID: 7987854
[TBL] [Abstract][Full Text] [Related]
22. Genetic polymorphism of urokinase-type plasminogen activator is interacting with plasminogen activator inhibitor-1 to raise risk of cervical neoplasia.
Tee YT; Wang PH; Tsai HT; Lin LY; Lin HT; Yang SF; Hsieh YH; Ying TH
J Surg Oncol; 2012 Aug; 106(2):204-8. PubMed ID: 22354580
[TBL] [Abstract][Full Text] [Related]
23. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.
Feng Q; Liu Y; Liu K; Byrne S; Liu G; Wang X; Li Z; Ockleford CD
Placenta; 2000; 21(2-3):184-93. PubMed ID: 10736241
[TBL] [Abstract][Full Text] [Related]
24. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade.
Baricos WH; Cortez SL; el-Dahr SS; Schnaper HW
Kidney Int; 1995 Apr; 47(4):1039-47. PubMed ID: 7540230
[TBL] [Abstract][Full Text] [Related]
25. Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice.
Teesalu T; Hinkkanen AE; Vaheri A
Am J Pathol; 2001 Dec; 159(6):2227-37. PubMed ID: 11733372
[TBL] [Abstract][Full Text] [Related]
26. The plasminogen-activating system in hepatic stellate cells.
Leyland H; Gentry J; Arthur MJ; Benyon RC
Hepatology; 1996 Nov; 24(5):1172-8. PubMed ID: 8903394
[TBL] [Abstract][Full Text] [Related]
27. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
28. Expression of urokinase-type plasminogen activator and its receptor during ovarian follicular development.
Li M; Karakji EG; Xing R; Fryer JN; Carnegie JA; Rabbani SA; Tsang BK
Endocrinology; 1997 Jul; 138(7):2790-9. PubMed ID: 9202219
[TBL] [Abstract][Full Text] [Related]
29. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
30. Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer.
Hazelbag S; Kenter GG; Gorter A; Fleuren GJ
Int J Cancer; 2004 Dec; 112(6):1020-8. PubMed ID: 15386352
[TBL] [Abstract][Full Text] [Related]
31. mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay.
Ramón L; Gilabert-Estellés J; Castelló R; Gilabert J; España F; Romeu A; Chirivella M; Aznar J; Estellés A
Hum Reprod; 2005 Jan; 20(1):272-8. PubMed ID: 15579491
[TBL] [Abstract][Full Text] [Related]
32. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
33. Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue.
Usher PA; Thomsen OF; Iversen P; Johnsen M; Brünner N; Høyer-Hansen G; Andreasen P; Danø K; Nielsen BS
Int J Cancer; 2005 Mar; 113(6):870-80. PubMed ID: 15515049
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of fibrinolytic activity of bovine aortic endothelial cells by ginsenoside Rb2.
Liu JW; Wei DZ; Du CB; Zhong JJ
Acta Pharmacol Sin; 2003 Feb; 24(2):102-8. PubMed ID: 12546716
[TBL] [Abstract][Full Text] [Related]
35. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
[TBL] [Abstract][Full Text] [Related]
36. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors.
Kumamoto H; Ooya K
J Oral Pathol Med; 2007 Sep; 36(8):488-94. PubMed ID: 17686008
[TBL] [Abstract][Full Text] [Related]
38. Temporal expression of urokinase plasminogen activator, plasminogen activator inhibitor and gelatinase-B in chronic wound fluid switches from a chronic to acute wound profile with progression to healing.
Wysocki AB; Kusakabe AO; Chang S; Tuan TL
Wound Repair Regen; 1999; 7(3):154-65. PubMed ID: 10417751
[TBL] [Abstract][Full Text] [Related]
39. Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells.
Gesualdo L; Ranieri E; Monno R; Rossiello MR; Colucci M; Semeraro N; Grandaliano G; Schena FP; Ursi M; Cerullo G
Kidney Int; 1999 Aug; 56(2):461-70. PubMed ID: 10432384
[TBL] [Abstract][Full Text] [Related]
40. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy.
Nicholas SB; Aguiniga E; Ren Y; Kim J; Wong J; Govindarajan N; Noda M; Wang W; Kawano Y; Collins A; Hsueh WA
Kidney Int; 2005 Apr; 67(4):1297-307. PubMed ID: 15780082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
